IGC Pharma (IGC) Stock Price, News & Analysis

Company Overview

IGC Pharma, Inc. is a life sciences company focused on developing and commercializing cannabinoid-based therapies and other plant-derived pharmaceutical products. Its research and development efforts have included treatments for neurological and neurodegenerative conditions, including Alzheimer’s disease, as well as products intended to address pain, seizures and other health-related needs.

The company has developed proprietary cannabinoid formulations and has pursued clinical development and regulatory advancement for its lead therapeutic candidates. It has also offered hemp- and cannabis-derived consumer products through its business operations, including products aimed at wellness and symptom management.

IGC Pharma was formerly known as India Globalization Capital, Inc., a company that historically operated in infrastructure and technology-related businesses before shifting its primary focus toward cannabis and pharmaceutical activities. The company is based in the United States and has maintained international business connections. Ram Mukunda serves as its chief executive officer.

Key Stats

• Today's Range: $0.27 to $0.28
• 50-Day Range: $0.24 to $0.33
• 52-Week Range: $0.24 to $0.45
• Volume: 630,614 shs
• Average Volume: 562,532 shs
• Market Capitalization: $28.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

IGC Pharma Stock Analysis - MarketRank™

IGC Pharma scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IGC Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

IGC Pharma has a consensus price target of $5.50, representing about 1,900.7% upside from its current price of $0.27.

Amount of Analyst Coverage

IGC Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGC Pharma are expected to grow in the coming year, from ($0.10) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGC Pharma is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGC Pharma is -3.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGC Pharma has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.36% of the float of IGC Pharma has been sold short.

Short Interest Ratio / Days to Cover

IGC Pharma has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IGC Pharma has recently increased by 48.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGC Pharma does not currently pay a dividend.

Dividend Growth

IGC Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.

Search Interest

1 people have searched for IGC on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IGC Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.87% of the stock of IGC Pharma is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:IGC
• Previous Symbol: NYSEMKT:IGC
• CIK: 1326205
• Web: www.igcinc.us
• Phone: (301) 529-4996
• Fax: 240-465-0273
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IGC Pharma: $5.50
• High Price Target: $5.50
• Low Price Target: $5.50
• Potential Upside/Downside: +1,900.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -99.21%
• Return on Assets: -74.18%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 0.39
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 22.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 3.44

Miscellaneous

• Outstanding Shares: 103,380,000
• Free Float: 78,923,000
• Market Cap: $28.42 million
• Optionable: N/A
• Beta: 0.47